65 results about "Enterococcus bacteria" patented technology

A general formula for lysins based on which the activity and functionality are further screened and 24 lysins are identified and further investigated, nine of which are characterized. These lysins exhibit potent bactericidal activity, capable of lysing multiple species of Staphylococcus, Streptococcus, and / or Enterococcus; demonstrate robust environmental resistance and stability, retaining activity under varying temperatures, NaCl concentrations, pH levels, and in immune serum; and effectively treat localized and systemic infections. These lysins and their variants are promising as antimicrobial agents for eradicating bacteria, preventing bacterial infections, or treating bacterial infections (caused by genera Staphylococcus, Streptococcus, and / or Enterococcus).

The invention provides an enterococcus faecium probiotic-prebiotics composite tablet and a preparation method thereof, and belongs to the technical field of microbial preparations. The tablet is prepared by taking enterococcus faecium (preservation number: CGMCC NO.33919) as a core active component, matching prebiotics adapted to the intestinal tracts of old people, a high-stability protective agent and mild auxiliary materials through a specific process. The tablet can efficiently adjust the intestinal flora structure of the old people, inhibit the proliferation of harmful bacteria in the intestinal tract and enhance the intestinal barrier function of the old people, so that the functional diarrhea and antibiotic-related diarrhea of the old people are relieved, and the tablet is moderate in hardness, easy to swallow, free of intestinal irritation and high in normal-temperature storage stability; the problems that an existing intestinal preparation is poor in adaptability to intestinal tracts of old people, strain activity is prone to inactivation, and swallowing is difficult are solved.

The invention discloses an enterococcus faecalis bacteriophage vBEfaPFA2, a bacteriophage composition and application of the enterococcus faecalis bacteriophage vBEfaPFA2, the enterococcus faecalis bacteriophage vBEfaPFA2 has a specific lysis effect on enterococcus faecalis and also has a cross-species lysis effect on salmonella, the acid-base adaptability of the bacteriophage is high, and the bacteriophage vBEfaPFA2 and the bacteriophage composition can be used for preparing the enterococcus faecalis bacteriophage The enterococcus faecalis bacteriophage can be used as an active component to be prepared into the bacteriophage composition or the bacteriophage pharmaceutical preparation, the bacteriophage composition or the bacteriophage pharmaceutical preparation is applied to preparation of a medicine or a bacteriostatic agent for preventing and treating enterococcus faecalis and salmonella infection, the enterococcus faecalis bacteriophage and the bacteriophage composition are safe to use, high in yield and easy to industrially produce, and due to the cross-species lysis performance, the bacteriophage can be The method has the advantages of wide splitting spectrum, wide application range and good application prospect.

The application discloses a brain hemorrhage prognosis improvement method based on intestinal flora regulation and relates to the technical field of intestinal microecology.The application comprises the following steps: detecting feces, starting intervention if the enterococcus abundance and neuroinflammatory metabolic markers exceed the standard, stopping the use of conventional nutrient solution, perfusing a special component containing sugar analogs, blocking the energy uptake of enterococcus, simultaneously providing a carbon source for beneficial bacteria, synchronously perfusing a microsphere suspension containing a molecular capture function, adsorbing and fixing proinflammatory metabolic waste in the intestinal tract, blocking the blood entry of the proinflammatory metabolic waste, perfusing live bacteria with different functions three times in time sequence, sequentially completing the acidification of the environment, constructing a bacterial membrane barrier and repairing the intestinal epithelium, and re-detecting after each round of intervention, selecting the maintenance period or adjusting the intensity and then recycling according to the decrease of enterococcus and markers.The application can limit the competitive advantage of enterococcus in the utilization of carbon sources after brain hemorrhage by sequentially implementing competitive inhibition of the phosphotransferase system and multi-species ecological niche occupation.

The invention discloses an antagonistic bacterium as well as a separation method and application thereof, and belongs to the technical field of microorganisms. The antagonistic bacterium is enterococcus durans XWK02002 obtained by separating and purifying intestinal tracts of marine live shrimps, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation date is October 20, 2025, and the preservation number is CGMCC No.36259. The invention further discloses a preparation method of the antagonistic bacterium. The enterococcus durans XWK02002 provided by the invention is high in specificity, has a remarkable inhibition effect on clinically-difficult multi-drug-resistant stenotrophomonas maltophilia, staphylococcus aureus and pseudomonas aeruginosa, and fills up the research blank of marine-derived enterococcus in resisting pathogenic bacteria.

The invention discloses a method for rapidly quantifying live bacteria coated with enterococcus faecium in feed and feed additives. The invention belongs to the technical field of biology, and particularly relates to a rapid quantification method for coating enterococcus faecium viable bacteria in feed and feed additives. The quantitative detection method for the viable bacteria of the coated enterococcus faecium in the feed and the feed additive comprises the following steps: 1) releasing the coated enterococcus faecium in the feed and the feed additive, and separating the viable bacteria of the enterococcus faecium; (2) carrying out molecular identification on the enterococcus faecium viable bacteria obtained in the step (1) by adopting enterococcus faecium specific identification primers; (3) analyzing the viable enterococcus faecium by adopting a quantitative equation to obtain the content of the viable coated enterococcus faecium in the feed and the feed additive.The method successfully solves the technical bottleneck that the viable coated enterococcus faecium is difficult to accurately quantify, shows excellent repeatability, stability and sensitivity, and has a good application prospect.

This invention belongs to the field of peptide drugs, specifically relating to an anti-drug-resistant bacterial peptide and its application in pharmaceutical manufacturing. Using Rink amide MBHA amino resin as a solid-phase support, the amino acid sequence of the template peptide raniseptin PL:Ac-GVFDTVKKIGKAVGKFALGVAKNYLNS-NH2 was modified, with amino acid residues 9I and 16F replaced by R8 and S5, respectively, to obtain the target stapling peptide PL-11. Compared to the template peptide PL-0, the stapling peptide PL-11 significantly enhances the antibacterial activity against Staphylococcus aureus, Enterococcus faecalis, and Staphylococcus epidermidis.

This invention belongs to the field of peptide drugs, specifically relating to an anti-drug-resistant bacterial peptide and its application in pharmaceutical manufacturing. Using Rink amide MBHA amino resin as a solid-phase support, the amino acid sequence of the template peptide raniseptin PL:Ac-GVFDTVKKIGKAVGKFALGVAKNYLNS-NH2 was modified, with amino acid residues 6V and 13V replaced by R8 and S5, respectively, to obtain the target stapling peptide PL-10. Compared to the template peptide PL-0, the stapling peptide PL-10 significantly enhances the antibacterial activity against Staphylococcus aureus, Enterococcus faecalis, and Staphylococcus epidermidis.

The invention discloses an application of a bupleurum chinense extract in preparation of an antibacterial product. According to the invention, it is found for the first time that various extracts (including aqueous extracts, ethanol extracts and extraction parts of different polar solvents) of bupleurum chinense have relatively good bacteriostatic activity on streptococcus pneumoniae, methicillin-resistant staphylococcus epidermidis, micrococcus luteus and enterococcus faecium. The antibacterial spectrums and effects of different extracts are different, and the research lays a solid foundation for developing novel anti-drug-resistant bacteria drugs and natural-source antibacterial products.

The invention belongs to the technical field of microorganisms, and in particular relates to enterococcus faecalis ZJUIDS-C010 with calcium enrichment capacity and application of the enterococcus faecalis ZJUIDS-C010. The invention discloses enterococcus faecalis ZJUIDS-C010, and the preservation number of the enterococcus faecalis ZJUIDS-C010 is CGMCC (China General Microbiological Culture Collection Center) NO. 34467. The invention also provides an application of the enterococcus faecalis ZJUIDS-C010 in increasing the utilization rate of calcium / enriching calcium at the same time. The enterococcus faecalis ZJUIDS-C010 can be used for preparing a product for promoting calcium absorption of intestinal tracts of pets.

The invention provides enterococcus faecalis bacteriophage vBEfaS-1017 and application thereof, the enterococcus faecalis bacteriophage vBEfaS-1017 is preserved in China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC NO.46182, and the preservation time is September 6, 2024. The bacteriophage vBEfaS-1017 is high in specificity, short in incubation period and ultrahigh in stability, and has activity under the conditions of extreme pH, high temperature and ultraviolet radiation; by evaluating the in-vitro bactericidal efficacy of the bacteriophage vBEfaS-1017, it is determined that the bacteriophage vBEfaS-1017 can effectively remove a biological membrane formed by host bacteria Ef 10-17, the removal rate is as high as 90%, and the bacteriophage vBEfaS-1017 is expected to become a scavenger for solving the biological membrane. Further experiments prove that the bacteriophage vBEfaS-1017 has in-vivo and in-vitro safety. Through combined use of the bacteriophage and different antibiotics, it is found that combined use of the bacteriophage vBEfaS-1017 and the antibiotic levofloxacin can effectively treat bacteremia of mice, the treatment time after infection can be prolonged by using the bacteriophage in advance, and the bacteriophage has a good application prospect in the aspect of preventing and treating enterococcus faecalis.

The invention discloses enterococcus durans BHDY002 and application thereof in preparation of products for promoting animal growth, and belongs to the technical field of microorganisms. The strain is preserved in the Guangdong Microbial Culture Collection Center on November 21, 2025, the preservation address is the 5th floor of the building 59, No.100 Courtyard, Xianlie Middle Road, Guangzhou, and the preservation number is GDMCC No: 67336. According to the invention, enterococcus durans with excellent tolerance is successfully screened from excrement samples of wild birds of wild angoraeae, and the probiotic potential and safety of enterococcus durans are verified through morphological observation, physiological and biochemical characteristic analysis, molecular biological identification and comprehensive evaluation of probiotic performance. The research widens the screening source of high-quality probiotic resources, widens the understanding of biological functions of enterococcus durans, and provides theoretical basis and strain resources for developing probiotic preparations for promoting animal growth, antagonizing pathogenic bacteria and regulating intestinal microecology.

Provided herein is an antimicrobial composition for hygiene applications. The antimicrobial composition comprises an effective concentration of a cathelicidin LL-37 peptide fragment in combination with an effective concentration of non- ionic surfactant. The non-ionic surfactant is an Alkyl-Poly Glucoside (APG) or alcohol ethoxylates or both. The antimicrobial composition further comprises of a chelating agent like disodium EDTA, or malic acid or citric acid or GLDA or PES A. The composition achieves log reduction of at least 3 against Gram negative bacteria Pseudomonas aeruginosa, Escherichia coll and Gram positive bacteria Staphylococcus aureus, Enterococcus hirae.

This invention belongs to the field of peptide drugs, specifically relating to an antibacterial peptide and its application in pharmaceutical manufacturing. Using Rink amide MBHA amino resin as a solid-phase support, the amino acid sequence of the template peptide raniseptin PL:Ac-GVFDTVKKIGKAVGKFALGVAKNYLNS-NH2 was modified, with amino acid residues 13V and 20V replaced by R8 and S5, respectively, to obtain the target stapling peptide PL-13. Compared to the template peptide PL-0, the stapling peptide PL-13 significantly enhances the antibacterial activity against Staphylococcus aureus, Enterococcus faecalis, and Staphylococcus epidermidis.

The invention belongs to the field of polypeptide drugs, and particularly relates to an antibacterial polypeptide and application thereof. According to the invention, Rink amide MBHA amino resin is used as a solid phase carrier, modification and transformation are carried out according to an amino acid sequence of a template polypeptide raniseptinPL: Ac-GVFDTVKKIGKAVGKFALGVAKNYLNS-NH2, and on the basis of retaining key amino acid residues, original amino acids are respectively replaced by S5 and R8 at amino acid positions i, i + 4 and i and i + 7, so that a target stapling peptide is obtained. Compared with a template polypeptide PL-0, the obtained stapled peptide has the advantage that the antibacterial activity on staphylococcus aureus, enterococcus faecium, enterococcus faecalis and staphylococcus epidermidis can be obviously improved.

The invention provides application of detection of enterococcus faecalis in liver cancer tissue in treatment of liver cancer. The invention finds that enterococcus faecalis is highly abundant in liver tumor tissues and is positively correlated with the pathogenesis of HCC (Hepatocellular Carcinoma). Enterococcus faecalis or an enterococcus faecalis conditioned medium promotes liver cancer cell proliferation, protein translation, cell migration and tumorigenesis. Animal experiments prove that colonization of enterococcus faecalis can promote in-vivo growth of liver cancer, and everolimus (an mTOR pathway inhibitor) administration can significantly inhibit the promotion effect. The colonization amount of the enterococcus faecalis can be used as a marker of a liver cancer clinical treatment strategy of colonization of the enterococcus faecalis.

The invention provides a method for preparing a calcium-rich product through fermentation of enterococcus faecium and application, calcium is enriched through fermentation of enterococcus faecium, ultrasonic treatment is carried out in the fermentation process, the calcium-rich capacity of enterococcus faecium is improved, the influence of calcium ions on the physiological activity of enterococcus faecium is researched, and the calcium-rich product is prepared by adjusting the variety and concentration of a carbon source and a nitrogen source. The formula of the fermentation culture medium is optimized, growth of the enterococcus faecium is promoted, the capability of converting inorganic calcium into organic calcium is enhanced, meanwhile, the antioxidant activity can be improved, and the enterococcus faecium fermentation culture medium has important significance on development of novel calcium supplements.

Provided is a pharmaceutical composition for preventing or treating benign prostatic hyperplasia or alopecia, comprising lactic acid bacteria of Enterococcus genus as an active ingredient. The pharmaceutical composition of the present invention can replace the conventional therapeutic agents against treating benign prostatic hyperplasia or alopecia, such as finasteride or dutasteride. In particular, by introducing heat-killed probiotics of Enterococcus faecalis, the effect of preventing or treating benign prostatic hyperplasia or alopecia can be further enhanced.

The application belongs to the field of polypeptide drugs, and particularly relates to an antibacterial polypeptide and application thereof in pharmacy. The application takes Rink amide MBHA amino resin as a solid phase carrier, and modifies and transforms according to a template polypeptide raniseptin PL:Ac-GVFDTVKKIGKAVGKFALGVAKNYLNS-NH2 amino acid sequence, wherein amino acid residues 19G and 26N are replaced by R8 and S5, to obtain a target stapled peptide PL-16. The stapled peptide PL-16 can significantly improve the antibacterial activity on Staphylococcus aureus, Enterococcus faecium, Enterococcus faecalis and Staphylococcus epidermidis relative to the template polypeptide PL-0.

The invention provides an enterococcus hirsutei and turmeric composition and application thereof in pet weight management, the composition comprises: (a) enterococcus hirsutei ZYpet-011, which is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.32007, the preservation date is September 20, 2024, the preservation number is CGMCC No.32007, the preservation number is CGMCC No.32007, the preservation number is CGMCC No.32007, the preservation number is CGMCC No.32007, the preservation number is CGMCC No.32007, the preservation number is CGMCC No.32007, and the preservation number is CGMCC No.32007; (b) turmeric and / or turmeric extract. Enterococcus hirsuteus and turmeric are compounded for the first time, safe, mild and long-acting improvement on dyslipidemia, liver burden and chronic inflammation of obese pets is achieved through the synergistic effect of strains and plant ingredients, lipid lowering, anti-inflammation and liver protection are achieved in a synergistic mode, and the effect of the composition is remarkably superior to that of a single component; a body weight and metabolism management solution which can be used for long-term feeding and has a stable effect is provided for obese pets, and the defects in the prior art are overcome.

The invention discloses an enterococcus faecalis bacteriophage vBEfaPFA3, a bacteriophage composition and application of the enterococcus faecalis bacteriophage vBEfaPFA3, the enterococcus faecalis bacteriophage vBEfaPFA3 has a specific lysis effect on enterococcus faecalis and also has a cross-species lysis effect on salmonella, the acid-base adaptability of the bacteriophage is high, and the enterococcus faecalis bacteriophage vBEfaPFA3 can be used as an active component to be prepared into the bacteriophage composition or a bacteriophage pharmaceutical preparation. The enterococcus faecalis bacteriophage and the bacteriophage composition are applied to preparation of drugs or bacteriostatic agents for preventing and treating enterococcus faecalis and salmonella infection, are safe to use, have no side effects, are easy to industrially produce, and are wide in lysis spectrum and wide in application range based on the cross-species lysis performance of the enterococcus faecalis bacteriophage and the bacteriophage composition.

The invention belongs to the field of medicinal chemistry, and discloses an aromatic pleuromutilin derivative with an antibacterial effect as well as a preparation method and application of the aromatic pleuromutilin derivative. The pleuromutilin is structurally modified, aromatic group modification is further increased through a reductive amination method after mercaptoethylamine is introduced into a C-14 side chain, and the structural formula of the pleuromutilin is shown in the specification. Research on an antibacterial mechanism finds that the series of derivatives can effectively interfere with expression of bacterial protein and show unique and excellent antibacterial activity, and the pleuromutilin can be applied to preparation of antibacterial agents. Compared with pleuromutilin in the prior art, most of the pleuromutilin compounds have antibacterial activity on staphylococcus aureus, escherichia coli, salmonella, micrococcus luteus and enterococcus faecalis which are common in in-vitro clinical application, hardly generate drug resistance, have stable safety and are expected to be further optimized into lead compounds of novel antibiotics.

The invention relates to the technical field of biology, in particular to an enterococcus bacteriophage capable of killing multi-drug-resistant enterococcus in cooperation with various antibiotics and application of the enterococcus bacteriophage. The collection number of the enterococcus bacteriophage CW7 provided by the invention is CCTCC NO: M 20252018, the enterococcus bacteriophage CW7 has good tolerance under the conditions that the pH is 3-11 and the temperature is 4-60 DEG C, and the titer of the enterococcus bacteriophage CW7 is up to 1.56 * 10 < 10 > PFU / mL after the enterococcus bacteriophage CW7 is cultured for 8 hours under the condition that the MOI is 0.01. Meanwhile, the bacteriophage is wide in antibacterial spectrum, short in incubation period, high in outbreak amount, capable of rapidly killing host bacteria, small in toxic and side effect, high in safety, wide in temperature and acid-base tolerance range, good in hydrophilicity and easy to prepare into an injection; meanwhile, the compound is combined with various antibiotics for use, so that a synergistic effect is achieved, and the compound has a very good sterilization and disinfection effect on animals infected with multi-drug-resistant enterococcus and environments and foods polluted by enterococcus.

The invention discloses enterococcus avium WZ03 and application thereof, and belongs to the technical field of microorganisms. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC) on July 3, 2025, the preservation number is CGMCC No.35092, and the strain is named as Enterococcus avium by taxonomy. The enterococcus avium WZ03 disclosed by the invention is screened and verified by a system, shows high protein preservation capacity and anti-mold property, has excellent fermentation performance and wide temperature and pH tolerance, and can adapt to variable environmental conditions. As an ensiling leavening agent, fermentation can still be stably started and the pH value can be continuously reduced under complex conditions such as temperature fluctuation or high-buffering raw materials, the putrefaction phenomenon caused by fermentation delay is effectively prevented, and an excellent strain resource is provided for improving the success rate and the stability of an ensiling process under adverse conditions.

The invention provides an application of a small molecule compound in preparation of antibacterial drugs. The small molecule compound is T-2307 or 0199-0032, and the T-2307 and the optimized analogue 0199-0032 of the T-2307, the antibacterial spectrum is wide, and the pertinence is strong. The T-2307 has obvious antibacterial activity on gram-positive bacteria (including staphylococcus aureus, staphylococcus epidermidis, enterococcus faecalis and enterococcus faecium), and has a certain inhibition effect on gram-negative bacteria such as escherichia coli and the like; the antibacterial activity of the T-2307 on gram-positive bacteria is inherited by the T-2307, the broad-spectrum antibacterial effect on gram-negative bacteria is further widened, the limitation of the T-2307 on the gram-negative bacteria is made up, and the T-2307 can be applied to preparation of broad-spectrum antibacterial drugs.

The present invention relates to a novel peptide comprising the amino acid sequence of SEQ ID NO: 1, and an antibacterial composition comprising same. The peptide of the present invention, which is an Enterococcus lactis-derived antibacterial peptide APP101, has specific antibacterial activity against periodontitis-causing bacteria including Porphyromonas gingivalis, Fusobacterium nucleatum, Enterococcus faecalis, Streptococcus parasanguinis, and Streptococcus salivarius, and has stability against proteases, pH, and salt concentrations. The antimicrobial composition of the present invention can be usefully employed for the prevention or treatment of periodontitis.

Methods comprising obtaining a biological sample and extracting nucleic acids from it are disclosed. The methods process the nucleic acids for DNA sequencing and identify in the DNA sequencing data a plurality of amplicon sequence variants (ASV). The methods record the relative abundance of each ASV and classify, using a machine learning algorithm, each ASV according to one of a set of taxonomies. The set of taxonomies includes a pathobiont bacteria subset consisting of genus level groups Eggerthella group, Ruminococcus torques group, Ruminococcus gnavus group, Coprobacillus group, Streptococcus group, Bilophila group, Actinomyces group, Desulfovibrio group, Atopobiaceae group, Veillonella group, Enterococcus group, Escherichia-Shigella group, Campylobacter group, Enterobacteriaceae group, and Fusobacterium group. Based on the relative abundance of the ASV classified as pathobiont bacteria, a numerical indication of the health of the subject is calculated. Based on the numerical indication, the methods deliver to the subject a customized intervention.

The application discloses a bacteriocin expressed by bacillus subtilis WB800N and application thereof. The original sequence of the bacteriocin is a bacteriocin PA from bacillus polymyxa, the nucleotide sequence of the bacteriocin PA is shown as SEQ ID NO:1, and the amino acid sequence is shown as SEQ ID NO:2. The bacteriocin PA coding gene is modified by a tag and optimized by a codon to obtain a bacteriocin PFH, the nucleotide sequence of the bacteriocin PFH is shown as SEQ ID NO:3, and the amino acid sequence is shown as SEQ ID NO:4. The bacteriocin PFH expressed by the bacillus subtilis WB800N has a good bacteriostatic effect on gram-positive bacteria such as streptococcus suis, enterococcus faecium, staphylococcus aureus and bacillus subtilis, and has a wide application prospect in the development of a new type of replacement product for infection treatment and a feed antibacterial peptide.

This invention discloses a chromium (VI)-resistant Enterococcus faecium, its isolation method, and its applications in the field of microbial technology. This chromium (VI)-resistant Enterococcus faecium, classified and named Enterococcus faecium, was deposited on October 24, 2025, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC NO.36330. The chromium (VI)-resistant Enterococcus faecium isolated by this invention can survive in high-concentration chromium (VI) environments and has a strong adsorption effect on hexavalent chromium, reducing the residue and bioaccumulation of hexavalent chromium in feed, thereby mitigating its toxicity to poultry.

The present application provides an antibacterial protein targeting Enterococcus gallinarum and a preparation method and application thereof. Specifically, the present application provides an antibacterial protein targeting Enterococcus gallinarum or a chimera thereof, wherein the antibacterial protein comprises one or more of the following proteins formed by the following amino acid sequences: (a) an amino acid sequence shown in any one of SEQ ID NO: 1 to SEQ ID NO: 9; (b) a derived sequence obtained by replacing, adding and / or deleting one or more amino acids from the amino acid sequence of (a) and having the same function as (a); and (c) a derived amino acid sequence having an identity of more than 85% or more than 90% with any one of SEQ ID NO: 1 to SEQ ID NO: 9. The antibacterial protein of the present application can efficiently kill Enterococcus gallinarum and has specificity.